GAITHERSBURG, MD, May 17, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial, a Phase 1/2 clinical study to evaluate the safety and efficacy of APT’s precision bacteriophage (“phage”) therapy in patients with Diabetic Foot Osteomyelitis (DFO). Traditional […]
News
Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis
Infectious disease and the need for more options
By learning from the past, we may have a much better arsenal against antimicrobial-resistant bacteria in the near future.
APT featured in Dutch Broadcast
Adaptive Phage Therapeutics was featured in an April 28 broadcast in the Netherlands, Dokters van morgen, discussing the treatment of stubborn infections. The discussion regarding APT begins at the 35 minute mark and features John Haverty (a patient helped by APT).
A Story of a Virus, Faith, and Hope That Saved His Life with John Haverty
“Never Give Up on Your Life” – John Haverty. John Haverty is a chef, a family man, a patient who was battling a stubborn bacterial infection in his leg for over 10 years. He wasn’t able to walk and put both feet on the ground for over 10 year. Doctors at Mayo Clinic were about […]
FDA Clears First Clinical Study for a Polymicrobial Phage Library-Based Treatment for Antibiotic-Resistant Infections
GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for the clinical development of APT’s phage bank™, a personalized bacteriophage therapeutic for […]
Phages Provide Safety Net In Post-Antibiotic Era
February 13, 2020 | To fully appreciate the potential of Adaptive Phage Therapeutics (APT), it’s helpful to review history through the lens of company co-founder and Chief Scientific Officer Carl Merril. For nearly five decades, Carl has been championing the idea of using bacteriophages to treat infectious diseases—an idea for which he has been variably applauded, questioned, ignored, scolded, and, ultimately, vindicated.
Adaptive Phage Therapeutics on NPR
Bacteriophage: A Force Of Nature As bacteria evolve to become more resistant to antibiotics, dangerous infections are taking their toll on human lives. We hear from John Haverty who, after knee replacement surgery generated an unrelenting infection … found himself facing amputation of his leg. Enter a new treatment called ‘phage therapy’ and Greg Merril, […]
Adaptive Phage Therapeutics Selected for Startup Grind’s Global 2020 Accelerate Program
Company is Recognized Top 1% among 4,000 applicants from 133 Countries GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that the company has been selected to participate in the Accelerate Program at the Startup […]
Adaptive Phage Therapeutics Awarded Initial Contract with Department of Defense
Funds Designated to Support Clinical Development of APT’s phage bankTM Precision Bacteriophage Therapeutic GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced the Department of Defense (DoD) has awarded APT a contract of $10.2 million […]
Hackensack Meridian Health Invests in Adaptive Phage Therapeutics, Aiming to Kill ‘Superbugs’ as Part of Bear’s Den Innovation Program
EDISON, N.J., Dec. 4, 2019 /PRNewswire/ — Hackensack Meridian Health has invested in the clinical-stage biotechnology company Adaptive Phage Therapeutics (APT), as part of the health network’s successful innovation program, the Bear’s Den. APT is taking aim at the toughest multi-drug resistant “superbugs” using precision-targeted, genomically-screened, and highly purified viruses known as bacteriophages, or “phages.”